

Ivanir Martins de Oliveira¹, Leila Maria Cardão Chimelli¹, Luis Felipe Ribeiro Pinto²

Authors affiliation: 1 – Divison of Pathology – Brazilian National Cancer Institute; 2 – Molecular Carcinogenesis Program – Brazilian National Cancer Institute

INTRODUCTION


- Stomach cancer is the fifth most common cancer in the world and the third leading cause of death.
- In Brazil, gastric cancer is the fourth most frequent in men and the fifth among women.
- Information on the HER2 expression in gastric (GA) and esophagogastric junction (EGA) adenocarcinomas may contribute to more effective treatments.
- The main objective of this study is to analyze the impact of HER2 overexpression on GA and EGA.

OBJECTIVE

To analyze the impact of HER2 overexpression on GA and EGA.

METHODOLOGY



- This study was based on a 1999-2006 retrospective cohort of patients operated at INCA, including 270 cases, of which 227 had primary GA and 43 patients with primary EGA.
- To determine the abundance of each immune cell population we applied signatures based on gene expression profile validated by Haroentong et al (2016)
- The clinicopathological data of the patients were obtained from the medical records and H&E slides were reviewed for histopathological data collection.
- The automated immunohistochemical technique was selected for HER2 detection



RESULTS

Well and moderately differentiated adenocarcinomas in the WHO category and intestinal type in the Lauren Classification

Low-differentiated adenocarcinomas with signet ring cells in the WHO category and diffuse type in the Lauren Classification



REFERENCES

- Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E3596.
- ANDERSON, W. F. et al. ge-specific trends in incidence of oncardiagastic cancer in US adults. *AMA: The Journal of the American Medical Association*, v. 303, n. 17, p. 1723-1728, 2010
- INCA. Estimativa de cancer no brasil 2016 [internet].
- Hoffman et al., Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology*, v. 52, p. 797-805, 2008

Funding source: Swiss Bridge Foundation, Ministério da Saúde, FAPERJ.

Projeto Gráfico: Setor de Edição e Informação Técnico-Científica / INCA